Vertex Pharmaceuticals Inc
F:VX1
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
315.55
475
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
VX1
stock under the Base Case scenario is
284.14
EUR.
Compared to the current market price of 392.3 EUR,
Vertex Pharmaceuticals Inc
is
Overvalued by 28%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Vertex Pharmaceuticals Inc.
| FR |
|
Pharnext SCA
OTC:PNEXF
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
|
| US |
S
|
Seagen Inc
F:SGT
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Vertex remains heavily dependent on its cystic fibrosis portfolio, and any slowdown in CF sales or an unexpected competitor breakthrough could significantly impact its top line.
Attempts to diversify into areas such as pain management and gene editing have yet to generate commercialized treatments, raising concerns about the long-term sustainability of its pipeline beyond CF.
High R&D spending and the premium pricing structure of its CF therapies may attract increased scrutiny from regulators and payers, potentially hurting margins.
Vertex’s CF franchise holds a dominant market position, with new therapies continually maintaining or expanding its share in this high-value therapeutic area.
Successful partnerships and investments in gene editing programs, including the CRISPR collaboration, offer promising new revenue streams and diversify its pipeline beyond cystic fibrosis.
The company’s robust balance sheet, combined with strong free cash flow from CF product sales, provides ample resources to fuel further R&D and strategic acquisitions.
Revenue & Expenses Breakdown
Vertex Pharmaceuticals Inc
Balance Sheet Decomposition
Vertex Pharmaceuticals Inc
| Current Assets | 10.6B |
| Cash & Short-Term Investments | 6.3B |
| Receivables | 1.9B |
| Other Current Assets | 2.3B |
| Non-Current Assets | 14.3B |
| Long-Term Investments | 5.7B |
| PP&E | 3B |
| Intangibles | 1.5B |
| Other Non-Current Assets | 4B |
| Current Liabilities | 4.5B |
| Accounts Payable | 4B |
| Other Current Liabilities | 441.5m |
| Non-Current Liabilities | 3.1B |
| Other Non-Current Liabilities | 3.1B |
Free Cash Flow Analysis
Vertex Pharmaceuticals Inc
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
Vertex Pharmaceuticals Inc
|
Revenue
|
11.7B
USD
|
|
Cost of Revenue
|
-1.6B
USD
|
|
Gross Profit
|
10.1B
USD
|
|
Operating Expenses
|
-5.6B
USD
|
|
Operating Income
|
4.5B
USD
|
|
Other Expenses
|
-861.3m
USD
|
|
Net Income
|
3.7B
USD
|
VX1 Profitability Score
Profitability Due Diligence
Vertex Pharmaceuticals Inc's profitability score is 60/100. The higher the profitability score, the more profitable the company is.
Score
Vertex Pharmaceuticals Inc's profitability score is 60/100. The higher the profitability score, the more profitable the company is.
VX1 Solvency Score
Solvency Due Diligence
Vertex Pharmaceuticals Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Vertex Pharmaceuticals Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
VX1 Price Targets Summary
Vertex Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
VX1
is 430.69 EUR
with a low forecast of 286.5 EUR and a high forecast of 545.16 EUR.
Dividends
Current shareholder yield for
VRTX is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
VX1
stock under the Base Case scenario is
284.14
EUR.
Compared to the current market price of 392.3 EUR,
Vertex Pharmaceuticals Inc
is
Overvalued by 28%.